Metabolic

GLP-1 receptor agonists drive 25–40% of total weight loss from lean tissue — a ratio that directly suppresses resting energy expenditure. Growth hormone secretagogues counter this via the GH→IGF-1→mTOR axis, stimulating muscle protein synthesis and preferentially mobilising visceral adipose tissue. The mechanistic case is strong; RCT-level co-administration data remain limited as of 2026.